| 000 | 01885 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250515032231.0 | ||
| 264 | 0 | _c20060912 | |
| 008 | 200609s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/sj.bmt.1705425 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKebriaei, P | |
| 245 | 0 | 0 |
_aAllogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cAug 2006 |
||
| 300 |
_a203-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aBurkitt Lymphoma _xtherapy |
| 650 | 0 | 4 | _aChi-Square Distribution |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xprevention & control |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma _xtherapy |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aStatistics, Nonparametric |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xmethods |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSaliba, R M | |
| 700 | 1 | _aMa, C | |
| 700 | 1 | _aIppoliti, C | |
| 700 | 1 | _aCouriel, D R | |
| 700 | 1 | _ade Lima, M | |
| 700 | 1 | _aGiralt, S | |
| 700 | 1 | _aQazilbash, M H | |
| 700 | 1 | _aGajewski, J L | |
| 700 | 1 | _aHa, C S | |
| 700 | 1 | _aChamplin, R E | |
| 700 | 1 | _aKhouri, I F | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 38 _gno. 3 _gp. 203-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bmt.1705425 _zAvailable from publisher's website |
| 999 |
_c16392768 _d16392768 |
||